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Abstract
We aimed to assess the relationship of the angiogenic
cytokines VEGF-A, VEGF-C, and VEGF-D and their
receptors VEGFR-2 and VEGFR-3 in the adenoma–
carcinoma sequence and in metastatic spread of color-
ectal cancer (CRC). mRNA expression levels were
measured using semi-quantitative reverse transcription
polymerase chain reaction in 70 CRC (35 with paired
mucosae) and 20 adenomatous polyps. Immuohisto-
chemistry and ELISA assessed protein expression.
VEGF-D mRNA expression was significantly lower in
both polyps and CRCs compared with normal mucosa
(P=.0002 and .002, respectively), whereas VEGF-A and
VEGF-C were significantly raised in CRCs (P=.006 and
.004, respectively), but not polyps (P=.22 and P=.5,
respectively). Receptor expression was similar in tumor
tissue and normal mucosae. Tumors with lymph node
metastases had significantly higher levels of VEGF-A
compared with non-metastatic tumors (P=.043). There
was no association between VEGF-C or VEGF-D and
lymphatic spread. The decrease in VEGF-D occurring in
polyps and carcinomas may allow the higher levels of
VEGF-A and VEGF-C to bind more readily to the VEGF
receptors, and produce the angiogenic switch required
for tumor growth. Increased expression of VEGF-A
within CRCs was associated with lymphatic metastases,
and therefore, this member of the VEGF family may be
the most important in determining metastatic spread.
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Introduction
Neoangiogenesis, the formation of new capillaries from pre-
existing blood vessels, is essential for tumor development
beyond a diameter of 2 to 3 mm3 [1]. This process is
mediated by angiogenic cytokines and provides tumors not
only with nutrients for growth, but also increases the
opportunity for tumor cells to enter the circulation and
metastasize [2]. The most potent of these cytokines is
vascular endothelial growth factor (VEGF-A), a heparin-
binding glycoprotein with potent angiogenic, mitogenic, and
vascular permeability–enhancing activities specific for endo-
thelial cells.
The gene for human VEGF-A is organised into eight
exons and located on chromosome 6 [3]. As a result of
alternative splicing, at least four transcripts encoding mature
monomeric VEGF containing 121, 165, 189, and 206 amino
acid residues (VEGF121, VEGF165, VEGF189, and VEGF206)
have been detected. The secretion pattern of the four
isoforms differs markedly. VEGF121 is a weakly acidic
polypeptide that does not bind to heparin, and is freely
soluble. VEGF165, the predominant form secreted by a
variety of normal and transformed cells [4 ], is a basic
heparin-binding glycoprotein. Although secreted, a signifi-
cant portion remains bound to the cell surface or extracellular
matrix. The VEGF189 isoform includes 24 additional amino
acids and is not freely secreted, but instead remains
predominantly bound to the cell surface and/or extracellular
matrix [5 ]. VEGF206 is a rare isoform, so far identified only in
a human fetal liver cDNA library.
VEGF-C and VEGF-D, two more recently discovered
cytokines, have not only angiogenic properties but also a
lymphangiogenic action. VEGF-C is 48% identical to VEGF-
D with long NH2- and C-terminal extensions, which set
VEGF-C and VEGF-D apart as a subfamily of VEGF-related
proteins.
VEGF-A acts through the tyrosine kinase receptors Flt -1
( fms- like tyrosine kinase) /VEGFR-1 and KDR (kinase
insert domain-containing receptor ) /VEGFR-2, which are
expressed on vascular endothelium. VEGF-C and VEGF-D
act through VEGFR-2 and Flt -4 /VEGFR-3 [6,7 ], a receptor
that in adult normal tissues is restricted to the lymphatic
endothelium and high venular endothelium of lymph nodes.
The pattern of expression of VEGF-C in relation to VEGFR-3
during the sprouting of the embryonic lymphatic endothelium
confirms its importance in developing lymphatics [8,9], with
overexpression of VEGF-C resulting in lymphatic endothelial
proliferation and selective hyperplasia of the lymphatic
vasculature [10]. Thus, the association of VEGFR-3 and
its two ligands with lymphangiogenesis has provided a
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possible mechanism for primary tumors to metastasize via
newly formed lymphatics and has led to studies investigating
VEGF-C and lymphatic spread [11–13].
The expression of VEGF-D in tumors has not been
extensively studied, but in adenocarcinoma of the lung,
VEGF-D levels were found to be significantly lower than in
normal tissue [14], whereas others have been unable to
detect VEGF-D expression in either tumor biopsies or the
colorectal cell line SW 480 [15].
This study shows the changes in expression of VEGF-A,
VEGF-C, and VEGF-D and their receptors VEGFR-2 and
VEGFR-3 through the adenoma–carcinoma sequence, and




Twenty adenomatous polyps, removed either surgically
or at colonoscopy, and 70 sporadic colorectal cancers
(CRCs), of which 35 had a paired normal mucosa sample
taken 10 cm from the primary tumor, were studied. There
were 7 with Dukes A, 22 with Dukes B, 27 with Dukes C,
and 14 with Dukes D carcinoma. Seven of the Dukes C/D
tumors had a positive lymph node taken from the mesentery
for comparison with the primary tumor. Colonic mucosa
from five benign resections was also taken. All samples
were snap- frozen and stored in liquid nitrogen until RNA
extraction.
Reverse Transcription Polymerase Chain Reaction
(RT-PCR)
Total RNA was extracted from the tumor samples using
SV Total RNA Isolation System (Promega, Madison, WI,
USA). Two micrograms of total RNA was diluted in 16 l of
double distilled water (DDW) and denatured at 958C for 5
minutes; oligo (dT) primer was added (5 l of 5 RT buffer
and 2 g of oligo (dT) ) and incubated for 15 minutes at 48C.
The primed RNA was reverse- transcribed and incubated for
60 minutes at 428C [5 l of M-MLV RT 5 buffer (Sigma,
St. Louis, MO, USA), 5 l of 1 mg/ml bovine serum albumin
(Sigma), 1 l of 5 U/l human placental ribonuclease
inhibitor (Promega rRNasin), 2 l of 350 mM  -mercaptoe-
thanol, 2 l of 25 mM dNTP (Sigma), 1 l of 200 mM sodium
pyrophosphate, 8 l of DDW, and 1 l of M-MLV reverse
transcriptase (Sigma)]. The cDNA was denatured for
5 minutes at 958C and stored at 208C until PCR.
PCR conditions were optimized such that the number of
cycles lays within the linear range of amplification. Five
microliters of cDNA was used for PCR reactions in a total
volume of 50 l of PCR mixture [1 l of 0.2 M sense and
antisense primer; 5.0 l of 10 PCR buffer (Sigma
REDTaq PCR reaction buffer 10 ), 5.0 l of 2.5 mM
dNTP (Sigma), 1.5 l of DNA polymerase (Sigma REDTaq
DNA polymerase) ]. Primers used are shown in Table 1.
PCR conditions were as follows: 28, 30, 32, 34, or 36
cycles of 1 minute at 948C, 2 minutes at 508C, and 1.0
minute at 728C for Beta-actin, VEGF-A, VEGFR-2,
VEGF-C, and VEGF-D, respectively. VEGFR-3 required
a hot start at 968C for 8 minutes, 568C for 3 minutes with
addition of 1.5 l of DNA polymerase, then 31 cycles of 1
minute at 948C, 2 minutes at 568C, and 1.0 minute at 728C.
Each PCR finished with an extension step of 10 minutes at
728C.
PCR was performed on 70 CRCs (35 with paired normal
mucosae), 20 adenomatous polyps, and 5 colonic mucosae
from benign resections in the case of VEGF-A, VEGF-C,
VEGF-D, and VEGFR-3. Due to insufficient cDNA, PCR for
VEGFR-2 was performed on 40 CRCs (14 with paired
normal mucosae), 13 adenomatous polyps, and 4 further
benign colonic mucosal samples.
PCR products were run on a 2% agarose gel with 0.1 g/
ml ethidium bromide. The gel was exposed to ultraviolet light
and the image captured using a Polaroid MP-4 Land
camera. Band intensity was analyzed by image analysis
(GelPro; Media Cybernetics, Silver Spring, MD, USA). The
intensity of the PCR products was semi-quantitated with the
intensity of their respective beta-actin band intensity, and is
expressed as arbitrary units.
Immunohistochemistry
VEGF-C and VEGF-D Four normal colonic resections, 11
adenomatous polyps, and 59 CRCs were examined. Paraffin
sections (5 m) were deparaffinized and placed in solution
of absolute methanol and 3% hydrogen peroxide for
30 minutes. After washing in distilled water and rinsing in
phosphate-buffered saline, slides were blocked with 1:10
diluted rabbit serum for 20 minutes. Slides were incubated
overnight at 48C in a humidified chamber with anti–VEGF-C
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti–
Table 1. Sequences of Primers Used for RT -PCR with Basepair Size.
Gene (bp ) Sense Primer Antisense Primer Size
 -Actin 50 - TCGACAACGGCTCCGGCA -30 5 -AAGGTGTGGTGCCAGATT -30 239
VEGF -A* 50 -CTCACCAAGGCCAGCACATAGG-30 50 -ATCTGGTTCCGAAAACCCTGAG-30 159, 291, 363, 414
VEGF -C 50 -GTCTGTGTCCAGTGTAGATG-30 50 -AGGTAGCTCGTGCTGGTGTT -30 360
VEGF -D 50 -CAGTGAAGCGATCATCTCAGTC-30 50 -TACGAGGTGCTGGTGTTCATAC -30 397
KDR /VEGFR-2 50 -GGAAATCATTATTCTAGTAGGCAC-30 50 -CCTGTGGATACACTTTCGCGATG-30 793
Flt - 4 /VEGFR-3 50 -AGCCATTCATCAACAAGCCT-30 50 -GGCAACAGCTGGATGTCATA-30 298
*Four isoforms of VEGF-A 121, 165, 189, and 206, respectively.
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VEGF-D (Santa Cruz Biotechnology) antibody diluted 1:100
with phosphate-buffered saline.
Slides were then incubated with biotinylated rabbit anti -
goat IgG for 20 minutes (Vectastatin ABC kits; Vector
Laboratories, Burlingame, CA, USA) and then with pre-
mixed ABC (Vector Laboratories) reagent for 20 minutes.
Immunostaining was performed by incubating the slides in
diaminobenzidine (Vector Laboratories). After chromogen
development, the slides were washed, counterstained with
hematoxylin, dehydrated with alcohol and xylene, and
mounted in routine fashion.
Negative controls were performed in all cases by omitting
the primary antibody. Cases with at least 20% immunor-
eactive tumor cells were considered positive, as described
previously [13].
VEGF-A Paraffin sections were deparaffinized and heated
in a microwave oven for 10 minutes in 10 mM sodium citrate
buffer, pH 6. Four normal colonic resections, 11 adenoma-
tous polyps, and 59 CRCs were examined. The slides were
then treated with a commercially available immunostaining
kit ( ImmunoCruz; Santa Cruz Biotechnology) using a mouse
monoclonal antibody [VEGF (C-1) ]. After chromogen
development with diaminobenzidine, slides were counter-
stained with Gill’s hematoxylin. Negative controls were
performed in all cases omitting the primary antibody. Cases
with at least 20% immunoreactive tumor cells were consid-
ered positive.
VEGFR-3 Fourteen randomly selected paraffin sections
were deparaffinized and heated in a microwave oven for 15
minutes in 10 mM sodium citrate buffer, pH 6. Endogenous
peroxidase was blocked using absolute methanol and 3%
hydrogen peroxide for 30 minutes. Slides were incubated
with 10% rabbit blocking serum, after which a mouse
monoclonal antibody 9D9 (a kind gift from Professor Kari
Alitalo, Helsinki, Finland) was added at a concentration of
1.1 l /ml for 2 hours at room temperature. Slides were then
incubated with biotinylated secondary antibody for 45
minutes (R&D Systems, Abingdon, UK), and then for 30
minutes with HSS-HRP (R&D Systems). Immunostaining
was performed by incubating the slides for 20 minutes with
AEC (3-amino-9-ethylcarbazole). After chromogen devel-
opment, the slides were washed, counterstained with
hematoxylin, and mounted in aqueous medium. Negative
controls were performed in all cases omitting the primary
antibody.
Quantitative Measurement of VEGF-A and VEGF-D
Protein Concentration
The total protein concentration of 25 tumor samples (16
with paired normal mucosae) was measured using
GeneQuant (Pharmacia, Cambridge, UK). These samples
were then assayed for VEGF-D protein (Figure 1 ) by
ELISA (R&D Systems), with 14 paired samples assayed
for VEGF-A (R&D Systems). The ELISA concentration
(pg/ml) obtained was divided by its total protein concen-
tration (g/ml) to correct for variation between samples,
producing a normalised ratio for each sample. No ELISA
for VEGF-C is commercially available at present.
Serum VEGF-D ELISA
Samples were obtained from 26 control patients who had
undergone a normal colonoscopy, 11 adenomatous polyp
patients, and 59 patients with CRC (7 Dukes A, 20 Dukes B,
18 Dukes C, and 14 Dukes D). These samples were assayed
for VEGF-D by ELISA (R&D Systems).
Statistics
The data were non-normally distributed and therefore
non-parametric tests were used. Comparison between
different data sets used an unpaired t - test (Mann-Whitney)
and comparison of paired data was calculated using
Wilcoxon’s rank test. The median value with interquartile
range ( IQR) is reported. Correlations ( two- tailed) were
calculated using the Spearman test. Statistical analysis was
performed on Prism 3 (GraphPad Software, San Diego,







































Figure 1. (A ) Comparison of corrected VEGF -D protein ratios in colorectal
cancers and paired normal mucosa (horizontal bar represents median ). (B )
Correlation of corrected VEGF-D protein ratios with RT -PCR products
( r=0.36, P= .03 ).
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CA). A P value of <.05 was considered statistically
significant.
Results
mRNA Expression of VEGF-A, VEGF-C, VEGF-D, KDR/
VEGFR-2, and Flt -4 /VEGFR-3
All CRCs, polyps, and normal mucosa expressed the
VEGF-A 121 and 165 isoforms, with only one cancer also
expressing the 189 isoform. A total of 67/70 (95.7%) CRCs,
18/20 (90%) polyps, and 38/40 (95%) normal mucosa
expressed VEGF-C; whereas 64/70 (91.4%) CRCs, 15/19
(78.9%) polyps, and 38/40 (95%) normal mucosa
expressed VEGF-D. A total of 29/40 (72.5%) CRCs, 10/
13 (76.9%) polyps, and 10/17 (58.8%) normal mucosa
expressed VEGFR-2; whereas 46/69 (66.6%) CRCs, 17/
20 (85%) polyps, and 33/39 (84.6%) normal mucosa
expressed VEGFR-3.
Comparison of CRC and Normal Mucosal Samples
VEGF-A 121 and 165 isoform expression was signifi-
cantly raised in CRCs compared to paired normal mucosae
[median 0.49 ( interquartile range 0.29–0.66) and 0.30
(0.19–0.42) vs 0.34 (0.25–0.49) and 0.22 (0.19–0.32),
P=.015 and P=.0045, respectively ]. As a consequence, the
total VEGF-A expression was significantly higher in CRCs
compared with normal mucosae [median 0.79 (0.48–1.04)
and 0.55 (0.44–0.83), P=.005, respectively ], and was
confirmed by ELISA measurement of normalised tumor
protein (0.478 vs 0.237, P=.0017, respectively). There was
a significant increase in VEGF-C expression in tumors
compared with paired normal mucosae [median 0.45
( interquartile range 0.32–0.68) and 0.37 (0.15–0.57),
P=.04]. However, there was a significant decrease in
VEGF-D expression in tumor tissue compared with paired
normal mucosae [median 0.32 (0.22 0.44) and 0.60 (0.40–
0.87), P=.0012].
The RT-PCR findings for VEGF-D were confirmed by
ELISA, which correlated with the RT-PCR data ( r=0.33,
P=.035), and showed that the expression of VEGF-D
protein in normal mucosa was significantly higher than the
paired tumors (median 0.107 and 0.288, respectively,
P=.0002) (Figures 1 and 2 ).
VEGFR-2 [median 0.19 (0–0.5) and 0.14 (0–0.32),
P=.45] and VEGFR-3 [median 0.23 (0.16–0.41) and 0.19
(0.09–0.32), P=.09] expressions were similar in tumor
tissue and normal mucosa.
VEGF-A, VEGF-C, VEGF- D, and the
Adenoma–Carcinoma Sequence
There was an increase in total VEGF-A from normal
mucosa to adenoma [median 0.53 ( interquartile range
0.43–0.82) and 0.67 (0.49–0.96), respectively, P=.22]
with a further increase in total VEGF-A in CRCs [0.78
(0.55–0.96), P=.006, compared to normal mucosa].
VEGF-C expression was higher in both polyps and CRCs
with very similar levels of expression [0.52 (0.24–0.61) and
0.52 (0.32–0.73) respectively ], but the differences were
only statistically significant between normal mucosa and
CRCs (P=.004). VEGF-D mRNA expression was signifi-
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Figure 2. VEGF -D RT -PCR products of five paired tumors (T ) and paired
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Figure 3. mRNA expression of VEGF-A, VEGF -C, and VEGF-D through the
adenoma–carcinoma sequence. Median values with interquartile range (box )
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Figure 4. Scatter plot of mRNA expression in normal mucosa, node -
negative, and node -positive tumors ( horizontal bar represents median ).
Table 2. VEGF -A, VEGF -C, and VEGF -D Immunohistochemistry.
VEGF -A VEGF -C VEGF -D
Normal mucosa (n=4 ) 0 ( 0%) 0 (0%) 0 (0%)
Polyps (n=11 ) 1 ( 9%) 0 (0%) 2 (18.2%)
Dukes A (n=11 ) 0 ( 0%) 1 (9.1%) 1 (9.1%)
Dukes B (n=18 ) 5 ( 27.7%) 12 (66.6%) 7 (38.8%)
Dukes C (n=22 ) 7 ( 31.8%) 8 (36.4%) 10 (45.5%)
Dukes D (n=8 ) 0 ( 0%) 1 (12.5%) 0 (0%)
Total number of cancers (n=59 ) 12 (20.3 ) 21 ( 35.6%) 18 (30.5%)
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cantly lower in both polyps and CRCs compared to normal
mucosa [0.29 (0.14–0.47), 0.37 (0.21–0.65), and 0.6
(0.4–0.86), respectively, P=.0002 and .002] (Figure 3 ).
There was no significant difference through the
adenoma–carcinoma sequence in the expression of the
two VEGF receptors.
VEGF-A, VEGF-C, VEGF-D, and Lymphatic Spread
The expression of VEGF-A and VEGF-C was signifi-
cantly higher in both node-negative and node-positive
tumors compared to normal mucosa. Comparison of the
tumors with reference to nodal status shows that node-
positive tumors had significantly higher VEGF-A mRNA
levels compared with node negative tumors [0.84 (0.58–
1.13) and 0.69 (0.45–0.89), respectively, P=.043]. How-
ever, there was no difference in VEGF-C expression
between node-negative and node-positive tumors (0.49
and 0.52 respectively, P=.77) (Figure 4 ).
VEGF-D expression was significantly reduced in both
node-negative and node-positive tumors, but there was no
significant difference between these categories.
A positive lymph node was harvested from seven patients
and compared with their matched primary tumor. There was
no significant difference between primary or lymphatic
metastasis expression of VEGF-A mRNA [median 0.91
(0.71–1.51) and 0.83 (0.72–1.52), P=.81, respectively ],
VEGF-C mRNA [median 0.63 (0.46–0.78) and 0.57 (0.4–
1.16), P=.94], or VEGF-D mRNA [median 0.44 (0.38–
0.64) and 0.03 (0.0–0.47), P=.31].
Immunohistochemistry
VEGF-A, VEGF-C and VEGF-D were expressed in
20%, 35%, and 31% of tumors, respectively, with staining
seen mainly in tumor cytoplasm (Table 2 and Figure 5 ).
VEGFR-3 was localised to the endothelial lining of vessels
around tumor cells. There was no correlation of positive
immunostaining and lymphatic spread.
Serum VEGF-D
Serum levels of VEGF-D were similar in normal controls,
polyp patients, and CRC patients [median 494 (303–744)
pg/ml, 416 (351–938) pg/ml, and 463 (291–745) pg/ml,
respectively ]. There was no statistical difference between
these groups.
Discussion
The role of the VEGF family in CRC has, to date, mainly
concentrated on VEGF-A, but the newer members of the
family of VEGF-C and VEGF-D may have important roles to
play in both angiogenesis and lymphangiogenesis. VEGF-C
and VEGF-D have been shown to have an angiogenic action
A B
C D
Figure 5. (A–D ) Immunostaining of tumor cytoplasm with VEGF -A (A ), VEGF -C (B ), VEGF -D (C ), and tumour endothelial cells with VEGFR-3 ( indicated by
black arrow ) (D ).
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on endothelial cells both in vitro and in vivo [16,17], and are
regulated by proinflammatory cytokines [18]. However, the
evidence that these two ligands both bind to VEGFR-3, a
tyrosine kinase receptor which is restricted to lymphatic
endothelium in normal adult tissues, has suggested that
VEGF-C and VEGF-D play an important role in lymphangio-
genesis [6,7,19].
VEGF-C mRNA expression was first reported in a mixed
population of tumors [20], and the functional association of
VEGF-C and VEGF-D with lymphangiogenesis has pro-
vided a possible mechanism for primary tumors to metasta-
size via newly formed lymphatics. Subsequent clinical
studies have reported a correlation between VEGF-C
expression and lymphatic spread in prostate [12], gastric
[13], thyroid [11,21], and neuroblastoma tumors [22].
In one study in CRC, the VEGF-C gene was found to be
poorly expressed with only moderate overexpression in
CRCs compared to control tissue [23]; however, numbers
were small (n=12). In a larger series of patients, protein
expression of VEGF-C (as measured by immunohistochem-
istry) correlated with lymph node spread [24].
The association of VEGF-C with lymphatic metastasis is
not universally seen in all tumor types. Our study demon-
strated no difference in VEGF-C mRNA expression relative
to lymph node status, similar to earlier reports in adenocar-
cinoma of the lung [14], breast cancer [25], and malignant
mesothelioma [26]. Interestingly, there was no significant
difference between VEGF-C mRNA expression of the
primary tumor and their paired positive lymph node meta-
stasis; however, numbers are small and comparison with
uninvolved lymph nodes is also required.
VEGF-C protein was expressed in 35% of CRCs as
detected by immunostaining and was localised to the tumor
cytoplasm. This is a lower frequency than reported in a
previous study in which 55 of 99 CRCs stained positive for
VEGF-C [24]. Unlike the previous study, we were unable to
show a correlation between VEGF-C and lymphatic spread
immunohistologically, confirming our mRNA expression
results. The difference in VEGF-C expression between
immunohistochemistry (35%) and RT-PCR (96%) is most
likely due to differing sensitivity between the methods, rather
than lack of translation of mRNA into protein.
VEGF-D mRNA is strongly expressed in normal tissue
such as skeletal muscle, heart, lung and intestinal mucosa
[7,15]. Early studies into VEGF-D expression in tumor cell
lines and tumor biopsy samples found expression to be
either weak or absent [15], and this has been confirmed in a
large study of lung adenocarcinomas [14].
Our study is the first to report on VEGF-D expression in
CRC. VEGF-D mRNA expression was significantly reduced
in tumors compared with normal tissue and this was
confirmed with quantitative protein measurements, similar
to head and neck [27]. Immunohistochemistry was positive
in 31% of tumors with staining localised to tumor cytoplasm,
similar to VEGF-C patterns.
Serum VEGF-A levels have been shown to correlate with
disease stage in CRC, with increasing levels being asso-
ciated with more advanced disease [28]. Serum VEGF-D
levels were not significantly different among control, polyp, or
CRC patients, and there was no association between serum
VEGF-D or VEGF-D mRNA expression and lymphatic
spread. Analysis of serum VEGF-C levels will be interesting,
but at present, there is no ELISA available.
VEGFR-3 mRNA expression was found in 74% of CRCs,
which is higher than the 40% reported in thyroid adenocarci-
nomas [29] and 53% in gastric adenocarcinomas [13]. In our
study, there was no difference in VEGFR-2 and VEGFR-3
mRNA expression among CRC tumors, polyps, or surround-
ing normal mucosa. Immunostaining localised VEGFR-3 to
the endothelial lining of blood vessels surrounding the tumor,
as reported in previous experimental [30] and clinical studies
[31,32]. Recently, it has been shown that solid tumors are
largely devoid of lymphatic capillaries, but are surrounded by
functional lymphatics in the adjacent normal tissue and
tumor periphery [33].
The expression of VEGF-A mRNA in normal colonic
mucosa is variable, ranging from 12% [34] to 73–100%
[35–37]. We detected the VEGF121 and VEGF165 isoforms
in all normal mucosal samples, and showed that both the 121
and 165 isoforms were significantly raised in CRCs
compared to normal mucosa. This was confirmed by
measuring tissue protein levels quantitatively using ELISA.
VEGF-C and VEGF-D mRNA were expressed in 96% and
90% of CRCs, respectively, and in 95% of normal mucosae.
VEGF-C, similar to VEGF-A, was significantly higher in
CRCs, but VEGF-D was significantly reduced in tumors
compared to normal mucosa.
Significant upregulation of VEGF-A mRNA expression in
adenomas compared to normal tissue, with a further
increase during development of adenocarcinomas, has been
reported previously [36], suggesting that angiogenesis is
stimulated early in colorectal tumorigenesis but continues to
increase during progression. Our results showed that both
VEGF-A and VEGF-C are increased in adenomas, but the
difference did not achieve statistical significance; however,
there was a significant decrease in VEGF-DmRNA. The role
of VEGF-D in tumors is largely unknown, but if VEGF-D acts
as a competitive agonist with VEGF-A and VEGF-C, the fall
in VEGF-D levels may allow VEGF-A and VEGF-C, which
are more potent angiogenic cytokines, increased access to
the two receptors. With VEGF-D remaining persistently low
in carcinomas compared with adenomas, and with constant
levels of the two receptors’ expression, if VEGF-A and
VEGF-C increase further within an adenoma, then the
angiogenic switch may occur later. This change in the
balance of different VEGF family members appears to be
significant, and others have shown that the ratio of VEGF-D
and VEGF-C is important for lymphatic invasion and
metastasis, with low levels of VEGF-D and high levels of
VEGF-C being associated with lymph node metastasis in
lung cancer [14].
The evidence that VEGF-A increases occur late in the
adenoma–carcinoma sequence is supported by immuno-
histochemistry studies [38]. In our study, only a single
polyp stained for VEGF, whereas others have failed to
demonstrate any positive staining [39,40]. Previous stud-
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ies have used polyclonal VEGF-A antibodies for immu-
nostaining and reported expression in 30% to 50% of
colorectal tumors [41–43]. Ours is the first study to use a
monoclonal VEGF-A antibody for immunohistochemistry,
which demonstrated VEGF-A positivity in 20% of CRCs,
and the increased specificity of the monoclonal antibody
may explain the lower percentage of positive tumors
compared to previous studies.
The aberrant isoform VEGF189 has been correlated
significantly with liver metastasis, vein involvement, and
poor prognosis in CRC cancer [34], and it has been
suggested therefore that the cell -associated isoform
VEGF189 is mainly associated with colon cancer progres-
sion. We detected the 189 isoform in only one tumor and we
and others have shown that it is the increase in the VEGF121
and VEGF165 isoforms which are associated with cancer
progression and lymphatic spread [35,37].
This study has shown that differences in the expression
of the VEGF family are important in the adenoma–
carcinoma sequence and subsequent cancer progression
and metastasis. The decrease in VEGF-D occurs both in
polyps and carcinomas and may allow the increased levels
of VEGF-A and VEGF-C to bind more freely with the
VEGFR-2 and VEGFR-3. These findings need to be
explored in in vitro studies by varying the balance of these
three angiogenic cytokines (recombinant human VEGF-C
is not yet available), and measuring the subsequent
angiogenic response. Increased expression of VEGF-A
rather than VEGF-C within CRCs was associated with
lymphatic metastases, and therefore, this member of the
VEGF family may be the most important in determining
metastatic spread.
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